Zentiva S.A (SCD) Fair Value & Analysis
Healthcare · RO · Market cap 3.2B RON
Fair value as of: Jul 27, 2026
From 14 valuation models · updated 14 days ago
Fair value updated Jul 27, 2026, revised from 6.11 RON to 1.17 RON (−80.9%) since Jun 26, 2026.
A solid business, but screening 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (2.14 RON). The favourable scenario is already priced in.
- The model range is unusually wide (0.5600 RON to 2.14 RON). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 27, 2026.
How to read this chart
60‑month range 1.80 RON – 4.52 RON · fair‑value band 0.5600 RON – 2.14 RON · the 4.52 RON price screens above the 1.17 RON fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 27, 2026.
Analysis
Zentiva S.A (SCD) currently trades at 4.52 RON, while our model-based Fair Value estimate is 1.17 RON, implying the stock looks roughly 74.1% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Zentiva S.A generated revenue of 1.1B RON at a net margin of 20.7%. Revenue grew 1.9% year over year. It earns a return on equity of 16.8%. The stock trades on a trailing P/E of 11.6. Fundamentals as of Jul 27, 2026
Our scenario range runs from 0.5600 RON (bear case) to 2.14 RON (bull case); at 4.52 RON, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -74%, SCD screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Multiples (6.11 RON) versus Asset-Based (1.39 RON). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally.
Full company description
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally. The company develops pharmaceutical products in various therapeutic areas, such as cardiovascular diseases, anti-inflammatory and pain-relieving medications, urologists, blood diseases, gastrointestinal and metabolic disorders, central nervous system, infections, respiratory systems, and other, as well as develops generic medicines. It also offers educational materials for healthcare professionals and patients. The company was formerly known as Sicomed S.A. and changed its name to Zentiva S.A. in January 2006. The company was founded in 1962 and is based in Bucharest, Romania. Zentiva S.A. is a subsidiary of Zentiva Group a.s.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Zentiva S.A reported revenue of 1.1B RON in FY2024 versus 558M RON in FY2020, a compound +18.9%/yr. Reported net income was 251M RON in FY2024, compounding +39.8%/yr from FY2020.
SCD screens 74% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Zentiva S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zentiva S.A (SCD) overvalued or undervalued?
What is the fair value of SCD?
What is the quality score of SCD?
What is the revenue of Zentiva S.A (SCD)?
What is the net profit margin of SCD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zentiva S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.